Brain Imaging and Mental Disorders of Aging Intervention

Inclusion Criteria: * Agreement to participate in a 18 month clinical trial * NIMH diagnostic criteria for age-associated memory impairment (AAMI) * Age 40 to 90 years * MMSE score between 24 and 30 (unless \< 8 years of educational achievement) * No significant cerebrovascular disease - modified Ischemic Score of \< 4 * The following medications are allowed if stable for \> 1 month: antidepressants (without anticholinergic effects) if not currently depressed and no history of major depression for 2 years; estrogen replacement therapy; thyroid replacement therapy as long as patient is euthyroid * On entering the study, there must be a family member or potential caregiver available in case the patient develops cognitive impairment that interferes with independent study participation. * Memory and verbal fluency cut-off scores increasing the probability of incipient dementia (Buschke-Fuld - 34; verbal fluency - 46 for letters, 7 for categories; Benton Visual Retention - 5) * Adequate visual and auditory acuity to allow neuropsychological testing * Screening laboratory tests and ECG without significant abnormalities that might interfere with the study Exclusion Criteria: * Diagnosis of possible or probable AD or any other dementia (e.g., vascular, Lewy body, frontotemporal) * Evidence of neurologic or other physical illness that could produce cognitive deterioration, including Parkinson's disease; volunteers with a history of TIAs, carotid bruits, or lacunes on MRI scan will be excluded * History of myocardial infarction within the previous year or unstable cardiac disease * Uncontrolled hypertension, history of significant liver disease, clinically significant pulmonary disease, diabetes, or cancer * Such current major psychiatric disorders as mania, according to DSMIV criteria, within the previous two years * Current diagnosis or history of alcoholism or drug dependence * Evidence of untreated depression * Use of any of the following drugs: centrally active beta-blockers, narcotics, clonidine, anti-Parkinsonian medications, antipsychotics, benzodiazepines, systemic corticosteroids, medications with significant cholinergic or anticholinergic effects, anti-convulsants, or warfarin; vitamins other than the standard multivitamin supplement, ginkgo biloba, and any nutraceuticals will not be allowed; once enrolled in the study, occasional chloral hydrate use will be allowed, but discouraged, for insomnia * Use of any investigational drugs within the previous month or longer, depending on drug half-life * Contraindication for MRI scan (e.g., metal in body, claustrophobia)